SSA
APLS

Schonfeld Strategic Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$380K – 1854
2023
Q3 		$380K Buy
+10,000
New +$439K ﹤0.01% 1276

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Schonfeld Strategic Advisors's APLS Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 123,824 shares worth $4.98M. The stake represents 0.04% of the portfolio and ranks #496 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in APLS as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in APLS in Q2 2018 and has held it in 19 quarters since. The position peaked at $15M in Q2 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Schonfeld Strategic Advisors held 123,824 shares of Apellis Pharmaceuticals worth $4.98M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.04% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #496 holding.
  • Schonfeld Strategic Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • Schonfeld Strategic Advisors's Apellis Pharmaceuticals position peaked at $15M in Q2 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.